Glucosylceramide Synthase

Glucosylceramide Synthase Products

  • All (4)
  • Glucosylceramide Synthase Inhibitors (3)
  • Glucosylceramide Synthase Modulator (1)
  • New Glucosylceramide Synthase Products
Catalog No. Product Name Information Product Use Citations Product Validations
S7852 Eliglustat Eliglustat (GENZ-112638) inhibits glucosylceramide synthase(GCS) (IC50=20 nM in intact MDCK cells), thus reducing the load of glucosylceramide influx into the lysosome.
Eur J Pharmacol, 2024, 966:176366
bioRxiv, 2024, 2024.10.10.617261
Int J Mol Sci, 2023, 24(12)9905
S4433 Eliglustat hemitartrate Eliglustat hemitartrate (Genz-112638, Eliglustat tartrate) is a potent, specific and orally active inhibitor of glucosylceramide synthase with IC50 of 24 nM.
Biochim Biophys Acta Mol Cell Biol Lipids, 2021, 1866(1):158817
Biol Pharm Bull, 2021, 44(10):1419-1426
E0646 Ibiglustat succinate Ibiglustat succinate (Venglustat succinate) is a glucosylceramide (GlcCer) synthase inhibitor that blocks the formation of glucosylceramide.
Cell Rep, 2023, 42(12):113431
E0786 N-Desmethyltamoxifen N-Desmethyltamoxifen, the major metabolite of Tamoxifen in humans and a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen, also is a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation.
S7852 Eliglustat Eliglustat (GENZ-112638) inhibits glucosylceramide synthase(GCS) (IC50=20 nM in intact MDCK cells), thus reducing the load of glucosylceramide influx into the lysosome.
Eur J Pharmacol, 2024, 966:176366
bioRxiv, 2024, 2024.10.10.617261
Int J Mol Sci, 2023, 24(12)9905
S4433 Eliglustat hemitartrate Eliglustat hemitartrate (Genz-112638, Eliglustat tartrate) is a potent, specific and orally active inhibitor of glucosylceramide synthase with IC50 of 24 nM.
Biochim Biophys Acta Mol Cell Biol Lipids, 2021, 1866(1):158817
Biol Pharm Bull, 2021, 44(10):1419-1426
E0646 Ibiglustat succinate Ibiglustat succinate (Venglustat succinate) is a glucosylceramide (GlcCer) synthase inhibitor that blocks the formation of glucosylceramide.
Cell Rep, 2023, 42(12):113431
E0786 N-Desmethyltamoxifen N-Desmethyltamoxifen, the major metabolite of Tamoxifen in humans and a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen, also is a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation.

Choose Selective Glucosylceramide Synthase Inhibitors

Tags: Glucosylceramide Synthase inhibitor|Glucosylceramide Synthase agonist|Glucosylceramide Synthase activator|Glucosylceramide Synthase inducer|Glucosylceramide Synthase antagonist|Glucosylceramide Synthase signaling pathway|Glucosylceramide Synthase assay kit